Address: Av. Kennedy 5454, 12th Floor, Vitacura, Santiago,Chile
Tel: +56 2 350 2479
Web: http://www.janssen.com.ar/chile/
Janssen-Cilag is a subsidiary of the Johnson & Johnson pharmaceutical company. The company was founded in the early 1950s by a merger between Janssen Pharmaceutica and Cilag AG.
Janssen-Cilag has an absolute commitment to patients, and promises to build innovative, integrated health care solutions that will restore and extend the quality of life, while creating economic value for society and the company. The aim is to achieve this by working side-by-side with healthcare stakeholders and by building on the talent of their employees.
The company has 6 research and development centers located in USA, France, Germany, Spain, Japan and Belgium, with more than 2500 scientists and researchers. It is from there that generates all the support and its subsidiaries provide information to physicians in over 175 countries for a safer practice of their profession.
Janssen-Cilag also has a pharmacovigilance department whose aim is to detect adverse effects of its drugs anywhere in the world, even those whose incidence is rare cases 1/100.000. The department serving Chile is based in Argentina.
Janssen-Cilag is actively developing treatments for patients in five important therapeutic areas of healthcare: cardiovascular and metabolic diseases, immunology, infectious diseases, neuroscience and oncology. The company’s complete solutions address some of the world’s most serious conditions and diseases.
More than just products and individual treatments, Janssen wants to provide solutions in disease management, including collaboration with private and public parties to monitor and manage health and prevent disease.
Research and development, cardiovascular and metabolic diseases, immunology, infectious diseases, neuroscience and oncology
Janssen-Cilag has been investing heavily in its Latin American operations in the past years. What is the relative importance of the Chilean operations for Janssen-Cilag in Latin America and what…
Eduardo Loyola has been at the helm of Heel’s Chilean affiliate for almost a decade. Prior to his appointment at Heel, Loyola was part of a working group that is…
Medtronic, world’s largest medical technology company, opened a direct operation in Chile in October 2013. Gonzalo Valdebenito elaborates on the affiliate’s first steps in the country and the mission he…
Cells for Cells is the first Chilean biotechnology company engaged in the research, development and commercialization of innovative cell therapies based on adult stem cells. In line with the company’s…
“We have implemented a strategic plan with a key objective to put Chile on the map. We are seeing major market opportunities in the country”, says Carlos Cicogna, Managing Director,…
Ciro Caravaggio, General Manager at Roche Chile discusses Roche’s mission as a highly specialized biotech with a long presence in Chile. He stresses the importance of the affiliate’s role in…
Raúl Sánchez, general manager of Peri Logistics speaks about the main features that distinguish Peri Logistics as a pharmaceutical logistics operator. Celebrating its 10th year anniversary this year, the company…
João Simões, Head of Integration at Grunenthal Chile, discusses Grunenthal’s acquisition of Andrómaco Laboratories. The acquisition has been a major step in Grunenthal’s growth strategy and has almost doubled its…
“70 percent of products on the Chilean market cannot demonstrate quality, safety and efficacy through bioequivalence studies”, explains Jean Jacques Duhart, Vicepresidente Ejecutivo of the association that represents the innovative…
Rodrigo Azócar Ibaceta, general manager at Laboratorios Raffo Chile speaks about Raffo’s development on the Chilean market. Part of the prestigious GP Pharm’s group, Raffo is one of the fastest…
Erich Viertel Molina, country manager at Janssen Chile speaks about Janssen’s commitment to the health of Chileans. Over the past years Janssen successfully launched several products to the Chilean market…
Pfizer will invest in a precision medical center studying new genome-based diagnostic technologies for cancer in Chile. It is the first center of excellence that Pfizer is building in Chile…
Our business model is new in the Chilean market and enables us with great flexibility and allows us to focus on demand generation. For Ferrer this is a great window…
See our Cookie Privacy Policy Here
